Ahn and colleagues (doi:10.1136/bmj.i6770) investigated the association between financial ties of principal investigators and outcomes in a random sample of 195 drug trials published in 2013.4 They found that trials authored by principal investigators with financial ties to drug manufacturers were more likely than other trials to